treatment persistence and switching patterns of an adalimumab biosimilar
Published 1 year ago • 541 plays • Length 3:31Download video MP4
Download video MP3
Similar videos
-
11:24
adalimumab biosimilar bi 695501 (cyltezo®; adalimumab-adbm) in rheumatoid arthritis
-
5:01
biosimilar adalimumab for patients with active rheumatoid arthritis
-
1:09
kalveer flora, mpharm: patient response to switching to biosimilar adalimumab
-
4:17
abp 501 biosimilar vs. adalimumab after single transition, papp et al
-
13:34
principles of biosimilarity - humira v amgevita
-
1:30
biologics and biosimilars: increasing treatment options
-
2:07
rationale for jak inhibition in pv
-
1:26:56
biosimilar medicines: changing patient care pathways, changing outcomes
-
1:09:11
biosimilars: what you need to know
-
1:50
interchangeability of biosimilars - video explainer
-
2:41
switching to biosimilars 2021
-
4:31
switch vs cycle in psa
-
1:42
innovator biologics vs. biosimilars vs. interchangeables
-
4:05
the border between brain treatment and brain enhancement
-
2:46
switching to biosimilars.
-
13:20
a phase 3 study of biosimilar bi 695501 versus adalimumab in patients with crohn’s disease - vjbm
-
0:17
biosimilars: more treatment options
-
21:12
positioning immunomodulators as monotherapies or in combination with biologics
-
1:28
comment: immunogenicity of biosimilars